From Glioblastoma Treatments
Jump to navigationJump to search
|
|
| (4 intermediate revisions by the same user not shown) |
| Line 1: |
Line 1: |
| {{TreatmentInfo
| | |
| |drug_name=Clomipramine (Chlorimipramine)
| |
| |FDA_approval=Yes (for depression and obsessive-compulsive neuroses)
| |
| |used_for=High-grade gliomas, including glioblastoma multiforme (GBM)
| |
| |clinical_trial_phase=Initial findings reported; further research needed
| |
| |common_side_effects=Known for its general tolerability; specific studies on glioma treatment might reveal more details
| |
| |OS_without=Median survival with traditional treatments like BCNU alone reported at 11 months
| |
| |OS_with=When combined with chloroquine, median survival extended to 25-33 months according to early studies
| |
| |PFS_without=Not specified
| |
| |PFS_with=Improvement in PFS-6 when combined with traditional chemotherapy agents
| |
| |usefulness_rating=3
| |
| |notes=Clomipramine, an antidepressant, has shown promise in treating high-grade gliomas by selectively depressing mitochondrial function in glioma cells, leading to apoptosis. Initial studies suggest potential efficacy in extending survival when combined with chemotherapy, though further detailed research is essential to validate these findings and explore mechanisms like autophagy inhibition.
| |
| |category=Repurposed Drugs
| |
| |links=
| |
| }}
| |
| |toxicity_level=4
| |
| |toxicity_level=4
| |
| |toxicity_level=4
| |
| }}
| |
Latest revision as of 09:27, 27 March 2024
